In search of new therapeutic targets for BC CML, we observed that miR-142 levels were significantly lower in mononuclear cells (MNCs), CD34+ HSPCs, and CD34+CD38− HSCs from BC CML patients compared with counterparts from healthy donors [HSCs: 4.2-fold lower (p = 0.002); Fig. 1a] or from CP CML patients [HSCs: 3.75-fold lower (p < 0.0001); Fig. 1a]. This evidence concerns the gene CD38 and breast cancer.